Search Result

Search Result

Results for "

BMDM macrophages

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) IFNAR (1) NO Synthase (6) NOD-like Receptor (NLR) (1) PD-1/PD-L1 (1) PI3K (1) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (3) Infection (6) Inflammation/Immunology (3)

10

Inhibitors & Agonists

6

Peptides

Targets Recommended: Macrophage migration inhibitory factor (MIF)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

SPSB2-iNOS inhibitory cyclic peptide-1	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

Antitumor agent-19	TNF Receptor	Cancer
Antitumor agent-19 is an antitumor agent that targets *tumor-associated macrophages* (TAMs) and can be used as a potent TAMs modulator. Antitumor agent-19 can increase TNF-alpha levels in tumor cells with EC₅₀** values of 17.18 μM and 18.87 μM in RAW 264.7 cells and BMDM cells, respectively .

TLR7 agonist 29	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 ADC Cytotoxin	Inflammation/Immunology Cancer
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC₅₀ of 5.2 nM for human TLR7 (EC₅₀ for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .

SPSB2-iNOS inhibitory cyclic peptide-2 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-2 (HY-P10384). SPSB2-iNOS inhibitory cyclic peptide-2 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 TFA is reduction-resistant and oxidatively stable .

SPSB2-iNOS inhibitory cyclic peptide-3 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-3 (HY-P10385). SPSB2-iNOS inhibitory cyclic peptide-3 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

SPSB2-iNOS inhibitory cyclic peptide-2	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 (Compound CP2) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 is reduction-resistant and oxidatively stable .

SPSB2-iNOS inhibitory cyclic peptide-3	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 (Compound CP3) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

NLRP3-IN-NBC6	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC₅₀= 574 nM) that acts independently of Ca ²⁺. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .

IHMT-PI3K-455	PI3K	Inflammation/Immunology Cancer
IHMT-PI3K-455 (Compound 15u) is a potent, selective, orally active PI3Kγ/δ dual inhibitor with IC₅₀s of 7.1 nM and 0.57 nM for PI3Kγ and PI3Kδ, respectively. IHMT-PI3K-455 suppresses the AKT phosphorylation. IHMT-PI3K-455 inhibits tumor growth by recruiting and activating more CD8 ⁺ killing T cells.IHMT-PI3K-455 is used in cancer research .

SPSB2-iNOS inhibitory cyclic peptide-1 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

Cat. No.	Product Name	Target	Research Area

SPSB2-iNOS inhibitory cyclic peptide-1	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

SPSB2-iNOS inhibitory cyclic peptide-2 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-2 (HY-P10384). SPSB2-iNOS inhibitory cyclic peptide-2 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 TFA is reduction-resistant and oxidatively stable .

SPSB2-iNOS inhibitory cyclic peptide-3 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-3 (HY-P10385). SPSB2-iNOS inhibitory cyclic peptide-3 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

SPSB2-iNOS inhibitory cyclic peptide-2	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-2 (Compound CP2) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 is reduction-resistant and oxidatively stable .

SPSB2-iNOS inhibitory cyclic peptide-3	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-3 (Compound CP3) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 7 nM .

SPSB2-iNOS inhibitory cyclic peptide-1 TFA	NO Synthase	Infection
SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with K_D of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator; DNA/RNA sequence conversion tools

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2025 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us